DNMWQ Stock Financial Analysis - Danimer Scientific, Inc.

Overview

Danimer Scientific, Inc., based in the United States, operates principally in the bioplastics industry. The company specializes in the development and manufacture of biodegradable materials, prominently leveraging polyhydroxyalkanoate (PHA), which is a biodegradable alternative to traditional plastics. Danimer Scientific focuses on producing renewable and sustainable biopolymers, which are used in a variety of applications ranging from single-use items such as straws and food containers to film packaging and coatings. Among its key initiatives, the company collaborates with major brands to reduce the environmental footprint of plastic products by enhancing their biodegradability. Danimer Scientific’s pursuit of scalable eco-friendly plastic solutions aligns with growing global demand for sustainable packaging solutions.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is 37.43 MM.
The operating income for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -86.87 MM.
The net income for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -111.20 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2024-09-30	37.43	-86.87	-111.20
2024-06-30	39.74	-99.29	-129.52
2024-03-31	44.98	-111.65	-146.10
2023-12-31	46.68	-125.19	-155.47
2023-09-30	51.06	-124.07	-144.09
2023-06-30	50.56	-124.31	-198.81
2023-03-31	50.40	-125.31	-190.01
2022-12-31	53.22	-123.94	-179.76
2022-09-30	55.62	-129.45	-164.15
2022-06-30	58.54	-129.87	-61.45
2022-03-31	60.31	-118.80	8.24
2021-12-31	58.75	-99.39	-60.11
2021-09-30	53.05	-71.10	-50.89
2021-06-30	52.51	-41.18	-60.86
2021-03-31	49.92	-21.66	-101.91
2020-12-31	47.33	-11.44	-8.85
2020-09-30	44.03	-7.76	-9.38
2020-06-30

Income Statement: EPS

The earnings per share basic for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -40.24.
The earnings per share diluted for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -40.24.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2024-09-30	-40.24	-40.24
2024-06-30	-48.83	-48.83
2024-03-31	-57.00	-57.00
2023-12-31	-60.97
2023-09-30	-56.61	-56.61
2023-06-30	-78.26	-78.39
2023-03-31	-74.96	-74.96
2022-12-31	-71.12
2022-09-30	-65.10	-64.96
2022-06-30	-24.55	-24.40
2022-03-31	3.40	3.40
2021-12-31	-25.83
2021-09-30	-26.78	-26.91
2021-06-30	-41.43	-41.51
2021-03-31	-93.05	-93.05
2020-12-31	-11.98
2020-09-30	-8.38	-8.50
2020-06-30	-3.01	-2.93

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -62.39 MM.
The cash from investing activities for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -8.28 MM.
The cash from financing activities for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is 15.12 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2024-09-30	-62.39	-8.28	15.12
2024-06-30	-58.07	-8.39	15.65
2024-03-31	-54.39	-13.23	5.53
2023-12-31	-47.26	-27.66	84.03
2023-09-30	-35.59	-56.56	83.21
2023-06-30	-45.59	-96.71	106.71
2023-03-31	-50.10	-139.97	113.21
2022-12-31	-61.84	-182.48	21.75
2022-09-30	-73.10	-240.16	217.76
2022-06-30	-77.72	-393.41	195.08
2022-03-31	-66.36	-371.19	332.85
2021-12-31	-62.96	-336.17	306.20
2021-09-30	-50.82	-260.73	501.70
2021-06-30	-26.05	-70.75	505.67
2021-03-31	-22.39	-46.81	369.10
2020-12-31	-13.80	-38.26	422.68
2020-09-30	-9.32	-45.97	51.30
2020-06-30

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Management Effectiveness

The roa for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -0.15.
The roe for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -0.37.
The roic for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -0.18.
The croic for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -0.09.
The ocroic for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -0.10.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2024-09-30	-0.15	-0.37	-0.18	-0.09	-0.10
2024-06-30	-0.19	-0.41	-0.22	-0.09	-0.08
2024-03-31	-0.22	-0.41	-0.23	0.01	-0.07
2023-12-31	-0.20	-0.37	-0.20	-0.01	-0.05
2023-09-30	-0.25	-0.42	-0.27	-0.05	-0.06
2023-06-30	-0.25	-0.42	-0.27	-0.05	-0.06
2023-03-31	-0.23	-0.39	-0.25	-0.10	-0.07
2022-12-31	-0.25	-0.31	-0.23	-0.14	-0.10
2022-09-30	-0.25	-0.31	-0.23	-0.14	-0.10
2022-06-30	-0.10	-0.12	-0.08	-0.36	-0.10
2022-03-31	0.02	0.03	0.01	-0.14	-0.09
2021-12-31	-0.11	-0.17	-0.08	-0.12	-0.08
2021-09-30	-0.28	-1.20	-0.09	0.33	-0.09
2021-06-30	-0.35	-1.55	-0.11	0.73	-0.05
2021-03-31	-0.70	-6.15	-0.30	0.88	-0.07
2020-12-31	-0.06	-0.51	-0.02	0.84	-0.03
2020-09-30		-0.35	-0.06	-0.03	-0.06
2020-06-30	-0.03	-0.11	-0.02	-0.10	-0.07

Gross Margins

The gross margin for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -0.64.
The net margin for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -2.97.
The operating margin for Danimer Scientific, Inc. - Equity Warrant as of September 30, 2024 is -2.32.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2024-09-30	-0.64	-2.97	-2.32
2024-06-30	-0.52	-3.25	-2.48
2024-03-31	-0.58	-3.33	-2.68
2023-12-31	-0.37	-2.82	-2.43
2023-09-30	-0.32	-3.93	-2.46
2023-06-30	-0.32	-3.93	-2.46
2023-03-31	-0.26	-3.77	-2.49
2022-12-31	-0.14	-2.95	-2.28
2022-09-30	-0.14	-2.95	-2.28
2022-06-30	-0.06	-1.05	-2.17
2022-03-31	0.00	0.14	-1.93
2021-12-31	0.05	-1.02	-1.69
2021-09-30	0.12	-0.96	-1.37
2021-06-30	0.19	-1.16	-0.87
2021-03-31	0.23	-2.04	-0.43
2020-12-31	0.27	-0.19	-0.33
2020-09-30	0.32	-0.21	-0.18
2020-06-30	0.33	-0.07	-0.16

DNMWQ Stock Financial Analysis - Danimer Scientific, Inc. - Equity Warrant (OTCPK) Stock